Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia.
In this study, we investigated the relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effect of pravastatin in patients with hyperlipidemia. A total of 179 patients were divided into two groups: the pravastatin (N = 97) and policosanol (N = 82) treatment groups. The total cholesterol (TC), triglyceride, low-density lipoprotein (LDL-c), high-density lipoprotein, ApoA, and ApoB concentrations in the serum were measured using an automatic biochemical analyzer before and after treatment for 12 weeks. The genotypes of the ApoA1 G75A SNP were detected by polymerase chain reaction-restriction fragment length polymorphism, and were subsequently statistically analyzed. Pravastatin treatment induced a significant decrease in the TC, LDL-c, and ApoB levels in patients expressing the ApoA1 AA+GA genotype (P < 0.05), and not in those expressing the GG genotype (P > 0.05). However, policosanol treatment induced a non-significant decrease in the serum TC levels (P > 0.05) and a significant decrease in the ApoB levels (P < 0.05), and did not induce a decrease in the LDL-c (P > 0.05) levels in patients with the AA+GA genotype. Policosanol also induced a significant decrease in the TC and LDL-c levels in patients with the GG genotype (P < 0.05). The various genotypes of the ApoA1 G75A SNP influence the efficacy of lipid regulation by pravastatin and policosanol in patients with hyperlipidemia.
Cardiovascular Division, Affiliated Hospital of the North China University of Technology, Tangshan, Hebei, China.
T N
TN
Liu
Cardiovascular Division, Affiliated Hospital of the North China University of Technology, Tangshan, Hebei, China.
C T
CT
Wu
Cardiovascular Division, Affiliated Hospital of the North China University of Technology, Tangshan, Hebei, China.
F
F
He
Cardiovascular Division, Affiliated Hospital of the North China University of Technology, Tangshan, Hebei, China.
W
W
Yuan
Cardiovascular Division, Affiliated Hospital of the North China University of Technology, Tangshan, Hebei, China.
S X
SX
Li
Cardiovascular Division, Affiliated Hospital of the North China University of Technology, Tangshan, Hebei, China.
H W
HW
Li
Cardiovascular Division, Affiliated Hospital of the North China University of Technology, Tangshan, Hebei, China.
H Y
HY
Yu
The People's Hospital of Tangshan, Tangshan, China.
M
M
Wu
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D016632:Apolipoprotein A-I / Q000235:genetics*; D005233:Fatty Alcohols / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D008074:Lipoproteins / Q000097:blood*; D020641:Polymorphism, Single Nucleotide; D017035:Pravastatin / Q000627:therapeutic use*
C505693:APOA1 protein, human; D000924:Anticholesteremic Agents; D016632:Apolipoprotein A-I; D005233:Fatty Alcohols; D008074:Lipoproteins; C080710:policosanol; D017035:Pravastatin